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Giant cell tumor is a benign primary bone neoplasm which most often occurs in a periartic-
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ular location. Involvement of the bones of the foot and ankle is rare, and there have been a
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limited number of previous case reports involving the talus. Here we report a case of giant
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cell tumor of the talus, which was initially radiographically occult in a 43-year-old female,
with emphasis on MRI imaging characteristics. The patient underwent surgical excision and
curettage. Histological examination revealed the presence of spindle cells admixed with gi-
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ant cells, confirming GCT. We further provide an overview of the radiological findings of

Giant Cell Tumor

GCT.

GCT

Giant cell tumor is a benign bone neoplasm of mesenchymal origin, identified by multin-

Talus

ucleated giant cells [1]. GCT is locally aggressive and can destroy adjacent bone and articulations. The most commonly affected bones are the distal femur, proximal tibia, and distal radius, with an epiphyseal predominance in 90% of cases [2]. Presentations are mostly
mono-ostotic, however multicentricity may occur in younger patients [3]. Very few cases
have been reported in the bones of the feet, an incidence of 1%-2% have been previously
reported [4].
GCT is seen between ages 20 and 40 years, with a 56% predominance in females [3]. Although
benign, 1%-9% cases may “metastasize” to the lungs. The initial treatment is surgical removal, either en bloc, or more commonly intralesional curettage and the use of adjuvants.
Even after resection, GCT has a high recurrence rate [2]. The trigger for GCT is currently
unknown. However, a majority of cases have cytogenetic abnormalities of telomeric associations (tas). Involvement of the RANK pathway is also believed to contribute to the pathogenesis of GCT [2].
© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington.
This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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Introduction
Case report
A 43-year-old female with a past medical history of partial
epilepsy presented for 1 month of progressive left ankle pain
following a fall. Three months prior to the fall, she had twisted
her ankle but did not seek medical treatment. Physical exam
revealed mild edema and tenderness of the lateral left ankle.
A left ankle radiograph showed a remote avulsion of the tip of
the lateral malleolus, but no bone or joint abnormalities were
noted. She was diagnosed with an ankle sprain (Fig. 1).
The patient was prescribed a walking boot and physical
therapy, without clinical improvement. At her 2 month followup visit, the physical exam revealed continued edema on the
anterior and lateral aspects of the left ankle, with tenderness
but no palpable mass. An MRI performed at this time demonstrated a well-circumscribed lesion of the talar neck with reactive bone marrow edema (Fig. 2).
The patient underwent a CT-guided core needle biopsy
which was inconclusive, but images demonstrated a well circumscribed lytic lesion in the talar neck with extension to the
articular surface (Fig. 3).
The needle biopsy revealed spindle cells admixed with giant cells and fibrous tissue. However, due to paucity of lesional
material, was considered nondiagnostic.
Subsequently, the patient underwent a left talus open
biopsy. Intraoperative fluoroscopy was used to confirm location of the lesion (Fig. 5). Frozen section analysis revealed spindle cells admixed with giant cells, fibrous tissue, and bone.
No malignancy was detected, and final diagnosis was deferred
until the permanent slides could be evaluated (Fig. 4A).
The patient returned to the clinic 2 weeks after open
biopsy. Pathology results were reviewed and showed GCT. The
patient was counseled for the recommendation of extended
intralesional curettage and use of adjuvants to appropriately
treat the GCT of bone. She declined to undergo another procedure at that time. The patient was informed that nontreated GCT is progressive in nature and prone to progression
with further destruction of the bone. The patient understood
but declined further treatment at the time. She was maintained on nonweight bearing precautions and was advanced
to weight bearing as tolerated 6 weeks after open biopsy. A radiograph was taken which demonstrated no evidence of fracture.
At 6 months status post open biopsy of the talus, ankle radiographs demonstrated progression of disease as expected
(Fig. 6). Intralesional curettage and use of adjuvants was recommended, to which the patient consented.
Follow-up CT shows increase in size of the previously seen
lytic lesion now measuring (approximately 2.2 × 2.1 × 2.4
cm (AP, transverse, and CC dimension), (previously measured
1.5 × 1.3 × 1.7 cm) in the medial aspect of the talar neck)
(Fig. 7A).
The patient then underwent an extended intralesional
curettage and use of adjuvants, including high-speed burr, dilute hydrogen peroxide, sterile water, and argon beam. The
talus was then filled with antibiotic impregnated cement with
added vancomycin. Postsurgical radiographs demonstrated

Fig. 1 – A remote avulsion lesion of the tip of the left lateral
malleolus noted with a well corticated bone fragment.
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GCT talus incidence of only 0.4% [5]. GCT is a benign bone neoplasm with characteristic multinuclear giant cells. The most
common presentation is in the early twenties to forties, with
a female predominance [3]. The etiology of GCT has not been
elucidated completely to date.

Fig. 2 – MRI of the left ankle. (A) Unenhanced axial TI MRI
depicting a well-circumscribed lesion in the medial aspect
of the talar neck extending to the articular surface at the
level of the medial facet of the subtalar joint. (B) Sagittal T1
MRI with contrast and fat suppression showing
enhancement of lesion with a thin sclerotic border. (C)
Unenhanced sagittal T2 demonstrates heterogenous
hyperintense signal with a thin sclerotic border.

cement-packing of the lesion and mild soft tissue edema
(Fig. 7B).
Histological examination from the second procedure, confirmed the presence of multinucleated giant cells (Fig. 4B).
Postsurgical treatment plan consisted of denosumab, chest
imaging, and regular ankle radiographs, to monitor for pulmonary metastasis and GCT recurrence. At 16 months after
the extended curettage, there was no evidence of bone resorption around the cement or GCT recurrence (Fig. 8).

Discussion
Giant cell tumor of the talus has been intermittently described
in the past. A search of literature on GCT of the talus in
PubMed revealed 28 cases of GCT of the talus, including case
reports and case series. Tumors presenting in the bones of the
feet have a reported incidence of 1%-2% [4]. However, a previous retrospective case series of 240 cases of GCT, found a

Radiographs
The primary diagnosis modality for GCT is radiography.
GCT is usually seen in long bones in 85% of cases, with
10% of cases reported in the axial skeleton and 1%-2%
in bones of the feet [4,6]. GCT presents as a radiolucent
lytic lesion with geographic bone destruction [1,3]. The
tumor can develop in the medulla as well as eccentrically. Over time eccentric lesions will grow and become
more centered and symmetric, especially in long bones [3].
Most commonly originating in the metaphysis, with extension into the subchondral bone plate and the epiphysis
[6,7].
GCT will present with well-defined non-sclerotic margins
in 80%-90% of cases, sometimes described as “moth eaten”
[7,8]. Sclerotic margins are uncommonly seen [3].
Less aggressive and early lesions usually do not interfere
with the cortex and have defined trabeculation [3,9]. More aggressive GCTs may present with cortical thinning and expansion, leading to periosteal elevation, and extension to surrounding tissues [6,10]. Furthermore, cortical destruction is
associated with pathologic fractures during initial presentation [6]. In GCT, tumor matrix mineralization (extracellular
space substance between tumor cells) is uncommon [3]. Lastly,
GCT exhibits a sharp narrow zone of transition normally located at the lesion margin [2]. However, more aggressive variants may show a wide zone of transition [10].

Fig. 3 – CT guided-needle biopsy demonstrating the lytic bone lesion of the talus.
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Fig. 4 – (A) Left talus open biopsy specimen with an even distribution of osteoclast-like giant cells (arrow) amongst
cytologically bland stromal cells. H&E ×100.(B) Left talus, curettage 6 months later. Photomicrograph highlights
multinucleate giant cells whose nuclei resemble those of the surrounding stromal cells. H&E ×400.

lesion on T1-weighted images [3]. T1 is preferred for intramedullary tumor characterization [9]. Gadolinium administration will result in heterogenous enhancement of solid components [11]. T2-weighted imaging will demonstrate a heterogenous hyperintense lesion. This sequence is preferred for
extraosseous involvement [3,11]. Additional findings can include low signal intensity for hemosiderin deposition most
identifiable on gradient echo sequences and fluid-fluid levels
in secondary bone cyst formation [3,13].

Findings of other talus lesions

Fig. 5 – Intraoperative bone biopsy with fluoroscopy,
revealing lytic lesion on talus.

CT
Staging, operative planning, and lesion progression assessment of GCT is commonly performed through computerized
tomography imaging [3]. CT imaging also visualizes certain
characteristics such as mineralization, cortical thinning, associated fractures, and extension of the lesion into soft tissues
more effectively [2,10]. CT is also favored over MRI for evaluating subtle cortical destruction. The presence of fluid-fluid
levels may also be observed, indicating secondary aneurysmal
bone cyst formation [3]. Due to the high vascularity of GCT, tumor blush may be exhibited on contrast-enhanced CT [7]. This
hypervascularity can lead to intratumoral hemorrhaging that
may be seen on CT imaging as well [3].

MRI
For more specific tumor characterization, MRI may be used.
GCT demonstrates homogenous, low to intermediate signal

Previous cases of GCT of the talus have also presented as a
radiolucent lytic lesion on radiographs, with most taking up
the whole talus or body [12,14–16]. Most cases displayed cortical thinning with a case showing multiple radiolucencies indicating osteolytic lesions have also been reported [12,14–17].
Expansion of the lytic lesion was also commonly seen [12,14].
Other radiographic findings included, narrowed joint spaces
and narrow zone of transitions. CT was beneficial for ruling
out extension into soft tissues, ligaments, and capsules, as
well as further characterizing cortical destruction and joint
space preservation [12,16]. For cases with MRI findings, these
were consistent with hypointense lesions in T1 and hyperintense lesions in T2. Enhancement of solid components was
also commonly seen [14]. One case described the tumor as
a solid cystic mass with multiple trabeculations, leading to a
heterogenous hyperintensity on T2 [14].

Radiographic differentials
Differentials for radiolucent lesions that should be considered
for radiographs include chondroblastoma, chondromyxoid fibroma, enchondromas, and chondrosarcoma. Osteosarcomas
and osteoblastomas are less commonly mistaken for GCT [8].
Defining characteristics of chondroblastoma include internal
matrix calcification with a thin sclerotic border usually seen in
the epiphysis of bones. Chondromyxoid fibroma arises will be
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Fig. 7 – (A) Unenhanced sagittal helical CT showing an
interval increase in size of the 2.4 cm well-circumscribed
lytic lesion, status post open biopsy. (B) Nonweight-bearing
ankle radiograph immediately status postcurettage, use of
adjuvants and cementation of talar lesion soft tissue
edema and ankle joint effusion from surgery.

Fig. 6 – Weight-bearing ankle radiograph after open biopsy
demonstrating progression of Giant Cell Tumor.

a lobulated lucent lesion in the metaphysis with a scalloped
sclerotic border [18]. Enchondromas are lytic lesions usually
located in the metaphyseal region that lack aggressive features, such as a periosteal reaction, endosteal scalloping [19].
Lastly, chondrosarcomas are malignant lesions that have a
unique ring-and-arc calcification pattern from chondroid matrix mineralization [20].

dral chondroblasts, amorphous chondroid, and chicken wire
pattern calcification. Few giant cells can be found scattered
in chondroid matrix. Chondroblastoma will stain positive for
S100 and have sometimes been found to express DOG1 [18].
ABCs have giant cells and macrophages lining cystic bloodfilled spaces. Histologically, chondromyxoid fibroma has very
few giant cells with fibrous tissue bands surrounding stellate
cell lobules. Chondromyxoid fibroma will stain for S100, SOX9,
and collagen III and express smooth muscle actin [18]. Langerhans cell histiocytosis have characteristic Langerhans cells,
which are ovoid cells with a lobulated nuclei. They will contain intracytoplasmic tennis racquet-shaped inclusion bodies
or Birbeck granules. The bone lesion will also contain some giant cells and eosinophil polymorphs that may form eosinophil
abscesses. Langerhans cell histiocytosis will be positive for
S100, CD68, HLA-DR, and Langerin [18]. Lastly, giant cell-rich
osteosarcoma will present with a high number of giant cells
which are evenly distributed, most characteristic by atypical
mitoses and nuclear pleomorphism representing malignant
features [18].

Pathological differentials

Treatment and prognosis

The most prominent characteristic of GCT pathologically is
the presence of multinucleated giant cells uniformly scattered
with mononuclear stromal cells [10]. Immunostaining will be
positive for CD45, CD68, and cathepsin K with some staining
for antihistone H3.3 G34W antibody [21].However, there are
other bone lesions that contain osteoclast-like giant cells include chondroblastoma, chondromyxoid fibroma, aneurysmal
bone cyst (ABC), Langerhans cell histiocytosis, and giant cellrich osteosarcoma [18]. Chondroblastoma will have polyhe-

The prognosis of GCT is favorable, only 5% of cases show pulmonary metastasis. Malignant transformation usually may
occur after radiotherapy [22]. Treatment often consists of extended intralesional curettage that may include adjuvants
such as phenol, high-speed burr, dilute hydrogen peroxide,
sterile water, argon beam, and liquid nitrogen [7]. After curettage, reconstruction may be done with bone grafts and cementation [22]. Recurrence occurs in up to 20% of cases. A
second intralesional curettage is then indicated [7]. In cases
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where surgery is not an option, radiation therapy or denosumab treatment may be used [22].
Although GCT of the bone is most often benign, there is a
small risk of malignant transformation [18]. Follow-up chest
radiographs are routinely performed to rule out lung metastases (seen in 1%-6% of GCT cases) [10].
Overall, GCT is a benign bone malignancy that has favorable prognosis after appropriate surgical intervention. Clinical signs include pain and edema over the ankle, at times with
tenderness as well [16]. Early presentations may be associated
with a sudden fracture. Therefore, suspicion should arise after
a pathological fracture in an unusual location, to ensure early
detection. The earliest recognition will often occur with a radiograph showing a lytic lesion. Further characterization of a
lytic lesion is recommended when found in unexpected areas
such as the talus. Careful search for other lesions is warranted,
since GCT of the talus may be multicentric in small bones [16].
Further imaging to confirm the presence of GCT benefits from
MR imaging. T1-weighted MRI will demonstrate a hypointense
or isointense lesion that will be hyperintense on T2-weighted
imaging. CT imaging is often preferred to investigate cortical
destruction, extension into soft tissues, and for surgical staging and planning. After resection, repeat imaging for the appearance of pulmonary metastasis or GCT recurrence is highly
encouraged.
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